These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20950165)

  • 1. Teriparatide for bone loss in the jaw.
    Grey A
    N Engl J Med; 2010 Dec; 363(25):2458-9. PubMed ID: 20950165
    [No Abstract]   [Full Text] [Related]  

  • 2. Teriparatide therapy for osteonecrosis of the jaw.
    Chtioui H; Lamine F; Daghfous R
    N Engl J Med; 2011 Mar; 364(11):1081-2; author reply 1082. PubMed ID: 21410382
    [No Abstract]   [Full Text] [Related]  

  • 3. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw.
    Cheung A; Seeman E
    N Engl J Med; 2010 Dec; 363(25):2473-4. PubMed ID: 20950167
    [No Abstract]   [Full Text] [Related]  

  • 4. More on the resolution of bisphosphonate-associated osteonecrosis of the jaw.
    Tsai KY; Huang CS; Huang GM; Yu CT
    J Rheumatol; 2010 Mar; 37(3):675; author reply 676. PubMed ID: 20197569
    [No Abstract]   [Full Text] [Related]  

  • 5. Teriparatide therapy for denosumab-induced osteonecrosis of the jaw in a male osteoporotic patient.
    Neuprez A; Rompen E; Crielaard JM; Reginster JY
    Calcif Tissue Int; 2014 Jul; 95(1):94-6. PubMed ID: 24804929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teriparatide and osseous regeneration in the jaw.
    Finkelman RD; Reddy MS
    N Engl J Med; 2011 Mar; 364(11):1080; author reply 1080-1. PubMed ID: 21410380
    [No Abstract]   [Full Text] [Related]  

  • 7. Teriparatide and osseous regeneration in the oral cavity.
    Bashutski JD; Eber RM; Kinney JS; Benavides E; Maitra S; Braun TM; Giannobile WV; McCauley LK
    N Engl J Med; 2010 Dec; 363(25):2396-405. PubMed ID: 20950166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are there any alternatives to alendronate (Fosamax) for osteoporosis to avoid the risk of osteonecrosis of the jaw?
    Wynn RL
    Gen Dent; 2007; 55(6):495-8. PubMed ID: 18050572
    [No Abstract]   [Full Text] [Related]  

  • 9. Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report.
    Narongroeknawin P; Danila MI; Humphreys LG; Barasch A; Curtis JR
    Spec Care Dentist; 2010; 30(2):77-82. PubMed ID: 20415805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fosamax and osteonecrosis of the jaw--important questions and answers.
    Wynn RL
    Gen Dent; 2008; 56(4):315-7. PubMed ID: 19284187
    [No Abstract]   [Full Text] [Related]  

  • 11. Study investigates novel approach to bone loss in the jaw.
    Garg A; Guez G
    Dent Implantol Update; 2011 Feb; 22(2):9-15. PubMed ID: 21425753
    [No Abstract]   [Full Text] [Related]  

  • 12. Bisphosphonate treatment as a cause of jaw osteonecrosis.
    Kanat O; Ozet A; Ataergin S; Kuzhan O; Arpaci F; Ozturk B; Komurcu S; Ozturk M
    Oral Dis; 2007 May; 13(3):346-7. PubMed ID: 17448221
    [No Abstract]   [Full Text] [Related]  

  • 13. [Osteonecrosis of the jaw secondary to oral alendronate: Report of three cases].
    Bocanegra-Pérez S; Vicente-Barrero M; Sosa-Henríquez M; Gebaguer Blanco A; Knezevic M; Castellano-Navarro JM
    Rev Med Chil; 2009 Feb; 137(2):275-9. PubMed ID: 19543652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate-induced osteonecrosis of the jaw.
    Sharma V; Nagaraj S; Choksey U; Hegde A; Samant R; Balakrishnan C
    J Assoc Physicians India; 2011 Aug; 59():516-7. PubMed ID: 21887911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comments on ''Geranylgeraniol--a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw" by Ziebart T et al. (2011).
    Marcuzzi A; Zanin V; Crovella S; Pontillo A
    Oral Oncol; 2011 May; 47(5):436-7; author reply 438. PubMed ID: 21411362
    [No Abstract]   [Full Text] [Related]  

  • 16. Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy.
    Lau AN; Adachi JD
    J Rheumatol; 2009 Aug; 36(8):1835-7. PubMed ID: 19671824
    [No Abstract]   [Full Text] [Related]  

  • 17. Osteonecrosis: what does it mean? One condition partly caused by bisphosphonates--or another one, preferably treated with them?
    Aspenberg P
    Acta Orthop; 2006 Oct; 77(5):693-4. PubMed ID: 17068696
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical concerns of alendronate use.
    Rutkowski JL; Johnson DA; Smith DM
    J Oral Maxillofac Surg; 2007 Feb; 65(2):363-4. PubMed ID: 17236956
    [No Abstract]   [Full Text] [Related]  

  • 19. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series.
    Fedele S; Porter SR; D'Aiuto F; Aljohani S; Vescovi P; Manfredi M; Arduino PG; Broccoletti R; Musciotto A; Di Fede O; Lazarovici TS; Campisi G; Yarom N
    Am J Med; 2010 Nov; 123(11):1060-4. PubMed ID: 20851366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of different doses and durations of teriparatide therapy on resolution of medication-related osteonecrosis of the jaw: A randomized, controlled preclinical study in rats.
    Zandi M; Dehghan A; Zandipoor N; Amini P; Doulati S
    J Craniomaxillofac Surg; 2018 Mar; 46(3):466-472. PubMed ID: 29395991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.